mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Clicks: 199
ID: 274869
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
199 views
39 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #8 of 12 articles by views in medRxiv : the preprint server for health sciences
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that were vaccinated recently (<3 months), distantly (6-12 months), or recently boosted, and accounted for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinated individuals. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron only 4-6-fold lower than wild type, suggesting that boosters enhance the cross-reactivity of neutralizing antibody responses. In addition, we find Omicron pseudovirus is more infectious than any other variant tested. Overall, this study highlights the importance of boosters to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (65 words).
Try re-searching for a better abstract.
| Reference Key |
garciabeltran2021mrnabasedmedrxiv
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Garcia-Beltran, Wilfredo F;St Denis, Kerri J;Hoelzemer, Angelique;Lam, Evan C;Nitido, Adam D;Sheehan, Maegan L;Berrios, Cristhian;Ofoman, Onosereme;Chang, Christina C;Hauser, Blake M;Feldman, Jared;Gregory, David J;Poznansky, Mark C;Schmidt, Aaron G;Iafrate, A John;Naranbhai, Vivek;Balazs, Alejandro B; |
| Journal | medRxiv : the preprint server for health sciences |
| Year | 2021 |
| DOI |
2021.12.14.21267755
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.